Effect of Dapagliflozin on Health Status and Quality-of-Life Across the Spectrum of Ejection Fraction: Participant-Level Pooled Analysis from the DAPA-HF & DELIVER Trials.
Niteesh K ChoudhryMikhail N KosiborodMuthiah VaduganathanBrian L ClaggettZ Michael MiaoIan J KulacCarolyn S P LamAdrian F HernandezFelipe MartinezSilvio E InzucchiSanjiv J ShahRudolf A de BoerPardeep S JhundAkshay S DesaiMagnus PeterssonAnna Maria LangkildeJohn J V McMurrayScott D SolomonPublished in: European journal of heart failure (2023)
In participant-level pooled analyses of DAPA-HF and DELIVER, dapagliflozin improved all key domains of health status across the full range of LVEF. Clinically meaningful improvements in health status were also observed consistently across the full range of LVEF, including in those with LVEF above 60%. This article is protected by copyright. All rights reserved.